alvelestat
Small molecule
Also known as MPH-966
Evidence outlook · lead readout
ASTRAEUS (NCT03636347) · Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
ASTRAEUS (NCT03636347): This was a randomized, double-blind, placebo-controlled study in 99 adults with alpha-1-antitrypsin-related lung disease; both alvelestat doses significantly reduced a blood biomarker of neutrophil elastase activity compared with placebo. Because the primary measure was a laboratory biomarker rather than a direct measure of lung symptoms or function, this is supportive but not definitive clinical evidence.
Also in development:Alpha-1 Antitrypsin Deficiency · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ASTRAEUS NCT03636347 · Alpha 1-Antitrypsin Deficiency, Emphysema, COPD This was a randomized, double-blind, placebo-controlled study in 99 adults with alpha-1-antitrypsin-related lung disease; both alvelestat doses significantly reduced a blood biomarker of neutrophil elastase activity compared with placebo. Because the primary measure was a laboratory biomarker rather than a direct measure of lung symptoms or function, this is supportive but not definitive clinical evidence. Registry: NCT03636347 | 2 | Change from baseline on blood biomarkers of neutrophil elastase activity compared to baseline and placebo (12 weeks) 2022-03-02 | Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Alpha-1 Antitrypsin Deficiency: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Alvelestat: this drug | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| Fazirsiran | Phase 3 | RNA / oligonucleotide | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| BEAM-302 | Phase 1/2 | Gene therapy / editing | SERPINA1 PiZ mutation (E342K) | not yet graded | No reviewed efficacy summary in this indication | |
| TSRA-196 | Phase 1/2 | Gene therapy / editing | SERPINA1 | not yet graded | No reviewed efficacy summary in this indication | |
| WVE-006 | Phase 1/2 | RNA / oligonucleotide | SERPINA1 Z-allele mRNA (ADAR-mediated editing) | not yet graded | No reviewed efficacy summary in this indication | |
| KB408 | Phase 1 | Gene therapy / editing | SERPINA1 (alpha-1 antitrypsin; gene replacement) | not yet graded | No reviewed efficacy summary in this indication | |
| Efdoralprin Alfa | —(overall) | Protein / enzyme therapeutic | Alpha-1 antitrypsin (AAT) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow alvelestat to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.